You have 9 free searches left this month | for more free features.

ocrelizumab

Showing 1 - 25 of 53

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Ocrelizumab Effects on the Metabolome in MS

Active, not recruiting
  • Multiple Sclerosis
  • Ocrelizumab
  • Baltimore, Maryland
    Johns Hopkins University
Jan 30, 2023

Ocrelizumab and Ofatumumab Administration in Relapsing Multiple

Completed
  • Relapsing Forms of Multiple Sclerosis
  • Lutherville, Maryland
  • +1 more
Oct 19, 2022

Symptom Burden in Patients Treated With Ocrelizumab for Multiple

Active, not recruiting
  • Multiple Sclerosis
  • Ocrelizumab
  • Wellesley, Massachusetts
  • +1 more
Oct 14, 2022

Multiple Sclerosis, Relapsing-Remitting Trial in Amsterdam (Ocrelizumab)

Recruiting
  • Multiple Sclerosis, Relapsing-Remitting
  • Ocrelizumab
  • Amsterdam, Noord-Holland, Netherlands
    Amsterdam UMC, location VU
Apr 21, 2022

Multiple Sclerosis Trial in United States (Ocrelizumab, Placebo for Ocrelizumab)

Recruiting
  • Multiple Sclerosis
  • Ocrelizumab
  • Placebo for Ocrelizumab
  • New Haven, Connecticut
  • +9 more
Jan 17, 2023

Multiple Sclerosis Trial in Moskva, Saint-Petersburg (Ocrelizumab)

Recruiting
  • Multiple Sclerosis
  • Ocrelizumab
  • Moskva, Moskovskaja Oblast, Russian Federation
  • +1 more
Aug 2, 2022

Ocrelizumab in Breastmilk

Active, not recruiting
  • Multiple Sclerosis
  • Clinically Isolated Syndrome
  • Ocrelizumab
  • San Francisco, California
    University of California, San Francisco
Mar 21, 2022

Physiological and Cognitive Changes in Multiple Sclerosis

Completed
  • Multiple Sclerosis
  • Ocrelizumab
  • Buffalo, New York
    Jacobs Institute
Mar 9, 2022

Multiple Sclerosis, Clinically Isolated Syndrome Trial in Worldwide (Ocrelizumab)

Recruiting
  • Multiple Sclerosis
  • Clinically Isolated Syndrome
  • Ocrelizumab
  • San Francisco, California
  • +5 more
Aug 2, 2022

Mechanistic Study of Ocrevus

Recruiting
  • Multiple Sclerosis
  • Ocrelizumab
  • Ann Arbor, Michigan
    University of Michigan
Jul 27, 2022

Multiple Sclerosis Trial in France (Ocrelizumab)

Recruiting
  • Multiple Sclerosis
  • Ocrelizumab
  • Amiens, France
  • +14 more
Jul 12, 2022

Relapsing Multiple Sclerosis, Clinically Isolated Syndrome Trial in San Francisco (Ocrelizumab)

Recruiting
  • Relapsing Multiple Sclerosis
  • Clinically Isolated Syndrome
  • Ocrelizumab
  • San Francisco, California
    University of California San Francisco
Apr 28, 2022

Multiple Sclerosis, Clinically Isolated Syndrome Trial in Worldwide (Ocrelizumab)

Recruiting
  • Multiple Sclerosis
  • Clinically Isolated Syndrome
  • Ocrelizumab
  • San Francisco, California
  • +9 more
Aug 2, 2022

WOE of Anti-CD20 Therapies

Not yet recruiting
  • Multiple Sclerosis
  • (no location specified)
Oct 31, 2023

Relapsing-Remitting Multiple Sclerosis Trial in Hamburg, Mannheim (Autologous Hematopoietic Stem Cell Transplantation,

Terminated
  • Relapsing-Remitting Multiple Sclerosis
  • Autologous Hematopoietic Stem Cell Transplantation
  • +2 more
  • Hamburg, Germany
  • +1 more
Mar 1, 2022

Ocrelizumab Access by Socio-Economic Status

Not yet recruiting
  • Multiple Sclerosis
  • Ocrelizumab
  • Boston, Massachusetts
    Brigham and Women's Hospital
Nov 22, 2021

Radiologically Isolated Syndrome, Multiple Sclerosis Trial in United States (Ocrelizumab, Placebo)

Recruiting
  • Radiologically Isolated Syndrome
  • Multiple Sclerosis
  • Ocrelizumab
  • Placebo
  • Los Angeles, California
  • +15 more
Jan 30, 2023

Autoimmune Encephalitis Trial in Dallas (Ocrelizumab, Saline)

Terminated
  • Autoimmune Encephalitis
  • Dallas, Texas
    UT Southwestern Medical Center
Sep 21, 2021

Relapsing Remitting Multiple Sclerosis Trial in Norway (Rituximab, Ocrelizumab)

Recruiting
  • Relapsing Remitting Multiple Sclerosis
  • Bergen, Norway
  • +10 more
Mar 18, 2022

Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Primary Progressive Multiple Sclerosis Trial

Recruiting
  • Relapsing Remitting Multiple Sclerosis
  • +2 more
  • Glostrup, Copenhagen, Denmark
  • +11 more
May 3, 2022

Multiple Sclerosis Trial in Italy, Poland, United States (Ocrelizumab)

Recruiting
  • Multiple Sclerosis
  • Ocrelizumab
  • Loma Linda, California
  • +22 more
Jan 13, 2023

Ocrelizumab on Peripheral Lymphocyte Immunophenotypes With

Not yet recruiting
  • Multiple Sclerosis
  • Ocrelizumab
  • Istanbul, Uskudar, Turkey
    Health Sciences University Istanbul Haydarpaşa Numune Training a
Aug 25, 2021

Relapsing Multiple Sclerorsis, Multiple Sclerosis, Primary Progressive Trial in Worldwide (Ocrelizumab, Lumbar Puncture,

Active, not recruiting
  • Relapsing Multiple Sclerorsis
  • Multiple Sclerosis, Primary Progressive
  • Ocrelizumab
  • +3 more
  • Palo Alto, California
  • +16 more
Jul 26, 2022

Multiple Sclerosis Trial in Aurora (Ocrelizumab, Rituximab)

Completed
  • Multiple Sclerosis
  • Aurora, Colorado
    University of Colorado Hospital
Jul 1, 2021

Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate

Recruiting
  • Multiple Sclerosis
  • Diroximel Fumarate
  • +8 more
  • Eden Prairie, Minnesota
    OptumInsight
Jan 9, 2023